C4 Therapeutics, Inc. — Director's Dealing 2020

Oct 7, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2020-10-06

Reporting Person: Salter Malcolm (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-06	Common Stock	C	11856	—	Acquired	11856	Direct
2020-10-06	Common Stock	C	2823	—	Acquired	14679	Direct
2020-10-06	Common Stock	P	1315	$19.00	Acquired	15994	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-06	Series A Preferred Stock	$	C	100000	Disposed		Common Stock (11856)	Direct
2020-10-06	Series B Preferred Stock	$	C	23809	Disposed		Common Stock (2823)	Direct

Footnotes

F1: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.